Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, May 21, 2024 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Seritage Growth Properties (NYSE: SRG) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Seritage Growth Properties investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On May 10, 2024, Seritage released its first quarter 2024 financial results, revealing total net operating income of $2.1 million, down from $8.6 million in the prior quarter. Additionally, the Company disclosed that it was “adjusting [its] pricing projections for some of [its] assets,” and issued a significant downwards revision to its asset valuations for future sales projections.
On this news, Seritage’s stock price fell $2.54, or 27.3%, to close at $6.78 per share on May 13, 2024, thereby injuring investors.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
- Imperial Petroleum Inc. Reports First Quarter 2025 Financial and Operating Results - May 23, 2025
- Etrion Releases First Quarter 2025 Results and Additional Return of Capital - May 23, 2025
- CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - May 23, 2025
